Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
NSCLC Stage IV|NSCLC, Recurrent
DRUG: Atezolizumab
Occurrence of Grade 3 toxicity, CTCAE v5.0, Cycle 1 day 1 to Cycle 3 day 1 (Each cycle is 21 days)|Occurrence of Grade 4 toxicity, CTCAE v5.0, Cycle 1 day 1 to Cycle 3 day 1 (Each cycle is 21 days)
Overall response rate (ORR) of participants, RECIST 1.1, Cycle 1 day 1 to Cycle 3 day 1 (Each cycle is 21 days)|Progression Free Survival (PFS), RECIST 1.1, From Cycle 1 day 1 (Each cycle is 21 days) for up to 2 years after end of treatment|1-year overall survival (OS) rate: Proportion of participants alive at 1 year from Cycle 1 day 1, Medical records, Cycle 1 day 1 up to 1 year post-Cycle 1 day 1 (Each cycle is 21 days)
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.